<DOC>
	<DOCNO>NCT01456104</DOCNO>
	<brief_summary>This study do see investigator help immune system work melanoma . A dendritic cell another type white blood cell . It , , proteins need make T cell work destroy cancer cell . However , dendritic cell normally cancer proteins surface . The challenge combine antigens dendritic cell make vaccine . The investigator think body 's T cell might react tumor help destroy . This study see altered dendritic cell make T cell work tumor cell . The dendritic cell make lab carry antigen . These cell inject skin . In study , investigator try help body make strong immune response cancer . The patient get kind dendritic cell vaccine use earlier study , one major difference . The dendritic cell contain messenger-RNA ( mRNA ) . Cells use mRNA make protein . The mRNA put dendritic cell laboratory method call electroporation . The mRNA never give patient directly . This mRNA help dendritic cell make tumor antigen like cancer express . The dendritic cell put tumor antigen surface body could make strong immune response tumor .</brief_summary>
	<brief_title>Immune Responses Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding Tumor-associated Antigen Patients With Malignancy : A Single-arm Phase I Trial Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis melanoma , AJCC stage IIB , IIC , III , IV ( MIa ) , histologic confirmation Department Pathology MSKCC . Patients must HLAA*0201 positive , base high resolution DNA level type . Expected survival great 3 month . Karnofsky performance status 70 high All patient undergone surgical treatment appropriate stage disease Patients may receive chemotherapy , immunotherapy , radiation within minimum 28 day ( minimum 42 day nitrosoureas mitomycin ) participation protocol . Pregnant lactate woman unknown risk fetus infant . Patients require systemic corticosteroid comparable exogenous immunosuppressive agent ( ) ( exclusion use NSAIDs ) . Patients know immunodeficiency ( e.g. , infection HTLV1,2 , HIV1,2 ; etc. ) . Patients coexist autoimmune disease , except vitiligo . Patients baseline impairment hematologic , hepatic , renal function ( CTCAE v4.0 &gt; grade 1 , ANC &lt; 1500 , hgb &lt; 10.0 g/dl , plts &lt; 75,000/ul , AST &gt; 3x ULN , creatinine &gt; 1.5xULN ) , assess within four week study entry . Patients organ allograft . Patients status post splenectomy status post splenic irradiation . Patients history document preexist retinal/choroidal disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>vaccine</keyword>
	<keyword>stage IIB</keyword>
	<keyword>stage IIC</keyword>
	<keyword>stage III</keyword>
	<keyword>stage IV ( MIa )</keyword>
	<keyword>Langerhans-type dendritic cell</keyword>
	<keyword>Immune Responses</keyword>
	<keyword>10-229</keyword>
</DOC>